A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
In 2001, Bruce Rothschild and others published a study examining evidence for stress fractures and tendon avulsions in theropod dinosaurs and the implications for their behavior. Since stress fractures are caused by repeated trauma rather than singular events they are more likely to be caused by regular behavior than other types of injuries. Of the 81 Tyrannosaurus foot bones examined in the study, one was found to have a stress fracture, while none of the 10 hand bones were found to have stress fractures. The researchers found tendon avulsions only among Tyrannosaurus and Allosaurus. An avulsion injury left a divot on the humerus of Sue the T. rex, apparently located at the origin of the deltoid or teres major muscles. The presence of avulsion injuries being limited to the forelimb and shoulder in both Tyrannosaurus and Allosaurus suggests that theropods may have had a musculature more complex than and functionally different from those of birds. The researchers concluded that Sue's tendon avulsion was probably obtained from struggling prey. The presence of stress fractures and tendon avulsions, in general, provides evidence for a "very active" predation-based diet rather than obligate scavenging. A 2009 study showed that smooth-edged holes in the skulls of several specimens might have been caused by Trichomonas-like parasites that commonly infect birds. According to the study, seriously infected individuals, including "Sue" and MOR 980 ("Peck's Rex"), might therefore have died from starvation after feeding became increasingly difficult.
"Patent Pending". FBI: Most Wanted. Season 4. Episode 6. 15 November 2022. CBS. "Via Negativa". The X-Files. Season 8. Episode 7. 17 December 2000. Fox Broadcasting Company. "Getting Off". CSI: Crime Scene Investigation. Season 4. Episode 16. 26 February 2004. CBS. "Users". Law & Order: Special Victims Unit. Season 11. Episode 7. 4 November 2009. NBC. "Echoes". Nikita. Season 1. Episode 16. 24 February 2011. The CW Television Network. "One Last Time". Homeland (TV series). Season 3. Episode 9. 24 November 2013. Showtime. "Bon Voyage". Graceland (TV series). Season 3. Episode 7. 6 August 2015. USA Network.
Marmite ( MAR-myte) is a food spread produced in New Zealand by Sanitarium Health and Wellbeing Company and distributed in Australia and the Pacific. It is similar to the British Marmite, but the two products are made by different companies. This is the only product sold as Marmite in Australasia and the Pacific, whereas elsewhere in the world the British version predominates. In the rest of the world it is sold as "NZ-Mite". Marmite has been manufactured in New Zealand since 1919. The product's popularity in England prompted the Sanitarium Health Food Company to obtain sole rights to distribute the product in New Zealand and Australia in 1908. They later began manufacturing Marmite under licence in Christchurch, albeit using a modified version of the original recipe, most notable for its inclusion of sugar and caramel. Common ingredients are also slightly different quantities from the British version; the New Zealand version has high levels of potassium, for example. New Zealand Marmite is described as having a "weaker" or "less tangy" flavour than the British version.
Sources: en.wikipedia.org
== Applications == The IM-MS technique can be used for analyzing complex mixtures based on differing mobilities in an electric field. The gas phase ion structure can be studied using IM-MS through measurement of the CCS and comparison with CCS of standard samples or CCS calculated from molecular modelling. The signal-to-noise ratio is obviously improved because the noise can be physically separated with signal in IM-MS. In addition, isomers can be separated if their shapes are different. The peak capacity of IM-MS is much larger than MS so more compounds can be found and analyzed. This character is very critical for -omics study which requires analyzing as many compounds as possible in a single run. It has been used in the detection of chemical warfare agents, detection of explosives, in proteomics for the analysis of proteins, peptides, drug-like molecules and nano particles. Moreover, IM-MS can be used to monitor isomeric reaction intermediates and probe their kinetics. Recently, microscale FAIMS has been integrated with electrospray ionization MS and liquid chromatography MS to rapidly separate ions in milliseconds prior to mass analysis. The use of microscale FAIMS in electrospray ionization MS and liquid chromatography MS can significantly improve peak capacity and signal-to-noise for a range of applications including proteomics, and pharmaceutical analysis. Recently, gas phase ion activation methods have been used to gain new insights into complex structures.
== Production == Thebacon is generated by the esterification product of the enol tautomer of hydrocodone (dihydrocodeineone) with acetic anhydride. Although modification of thebaine is the most common way of making thebacon, preparation by refluxing hydrocodone with acetic anhydride is not uncommon, generally similar to how diacetylmorphine is produced. It is also a product of the metabolism of hydrocodone by Pseudomonas putida M10, the bacterium used for oil spill remediation. This also produces a morphinone reductase, which can turn morphine into hydromorphone in a process which produces other active opioids, such as oxymorphone, oxymorphol, or hydromorphinol as intermediates.
In addition, they announced plans to conduct a phase 2b study of enobosarm at doses of 3 to 6 mg/day for this purpose in sarcopenic obese or overweight elderly individuals receiving GLP-1 receptor agonists. Enobosarm was developed by GTx, Inc., and is now being developed by Veru, Inc.
Sources: en.wikipedia.org
=== Mechanical behavior === The mucus of the gastropods contained positively charge polypeptides and negatively charged polysaccharides that form a dissipative matrix. This contributes to the mechanical strength and toughness of the hydrogel. Tensile strength of dried snail mucus gel of the Achatina fulica species reached 82.59 ± 7.39 kPa. In addition to tensile properties, gastropod adhesives have significant pel strength. This high peel resistance is due to the double interpenetrating network structure, where the deformable network dissipates energy whole the stiffer network maintains structural integrity. As a result, the adhesive can sustain large deformations and distribute stress over a larger area. The combination of energy dissipation and strong interfacial bonding allows the adhesive to adhere to wet and irregular biological surfaces.
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. As of 2016, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". The drug was rejected for FDA approval in 2017 and 2020.
==== Alzheimer's disease ==== There is indirect evidence to suggest that system Xc- might be upregulated in Alzheimer's patients. It has been found in Alzheimer's patients that there is an increase in phosphorylation of the alpha subunit of eukaryotic initiation factor 2 and in expression of transcription factor 4, both of which increase system Xc- expression. It has also been shown that administration of N-acetylcysteine leads to a significant improvement in certain cognitive tasks for Alzheimer's patients.
Geraniol 8-hydroxylase (EC 1.14.14.83, formerly EC 1.14.13.152, CYP76B6, G10H, CrG10H, SmG10H) is an enzyme with systematic name geraniol,NADPH:oxygen oxidoreductase (8-hydroxylating). This enzyme catalyses the following chemical reaction:
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.